Skip to main content

CeMines Opens New Division in Estonia

NEW YORK, Dec. 3 (GenomeWeb News) - CeMines has created a new operating division in Estonia called CeMines International, which will become a wholly owned subsidiary of CeMines, the company said today.

 

In Estonia, CeMines will "expand [its] research-and-development initiatives, establish a regulatory-affairs presence in the European Union and accelerate commercialization of new methods and technology," according to CEO Roger Attick.

 

"A comprehensive international business strategy is central to long-term competitive advantages," Attick added. CeMines will also leverage its presence in Europeto cultivate new research partnerships and distribution channels."

 

CeMines, based in Golden, Colo., is developing its molecular fingerprinting technologies for early-stage diagnostics and therapeutics.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.